To our knowledge, this is the first real-world-study-based CEA of using GLP-1RAs versus insulin for T2D patients who require a greater glucose-lowering effect of injection therapy, and the first systematic review on this topic. This evidence concerns the gene INS and type 2 diabetes mellitus.